Navigation Links
Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol
Date:4/26/2010

HOERSHOLM, Denmark and SAN DIEGO, April 26 /PRNewswire/ -- Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.

High cholesterol is a major risk factor for coronary heart disease, heart attack and stroke. According to the World Health Organization, high cholesterol is estimated to cause 18% of strokes and 56% of heart disease, globally and amounts to approximately 4.4 million deaths and 40.4 million disability-adjusted life years(1).

Santaris Pharma A/S presented preclinical data on SPC5001 last month at the PCSK9 Conference "From gene to therapeutics" in Nantes, France where many top pharmaceutical companies gathered to discuss efforts to develop therapies aimed at inhibiting the important new target PCSK9, a protein involved in regulating LDL (low-density lipoprotein) or "bad" cholesterol in the blood.

Data presented by Santaris Pharma A/S scientists showed that SPC5001 provided potent, specific and long-lasting inhibition of PCSK9 and lowered mean LDL cholesterol by 50% in non-human primates with a sustained reduction of 74% in the highest responder. SPC5001 did not change HDL (high-density lipoprotein) levels or the "good" cholesterol in the blood(2). The preclinical data suggest that SPC5001 has the potential to provide patients with a new treatment opti
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
5. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
6. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
7. New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations
8. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
9. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Quebec , November 21, 2014 ... wechselt als Chief Commercial Officer zu KLOX ... SVP der Unternehmensentwicklung und Chief Financial Officer bestellt    ... Europa mit der Vermarktung seines jüngst zugelassenen Behandlungssystems zur ... Inc. ("KLOX" bzw. das "Unternehmen") ist sehr erfreut, die ...
(Date:11/21/2014)... --  TRU-D SmartUVC LLC and its UK partners, Rapid ... robot, TRU-D SmartUVC, at FIS 2014 in Harrogate, ... at Stand 23. The conference, hosted by Federation ... largest infection-related event of its kind and brings together ... leading events of its type throughout the world. This annual ...
(Date:11/21/2014)... November 20, 2014 Offering a complete ... Sartorius Entris Balance promotion . The Sartorius Entris Balance ... durable, high accuracy, and easy-to-maintain balance entry level balance. ... It was designed to help customer’s bridge the gap ... balance that is very durable. Sartorius is the second ...
(Date:11/21/2014)... Alto, Calif. (PRWEB) November 20, 2014 ... a nonprofit, public policy research organization representing leading ... pharmaceutical firms, and PwC US today ... states in life sciences industry growth. The trend ... 2013. The 2015 California Biomedical Industry Report ...
Breaking Biology Technology:KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3Pipette.com Announces an Extension on the Sartorius Entris Balance Promotion to the End of 2014 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4
... signed into law Senate Bill 338, which is designed ... in the way of University of Wisconsin researchers. , ... turn research ideas into potential business opportunities. He said ... faculty and staff try to start businesses based on ...
... San Francisco or Boston, and youre on the verge of investing ... right: The management team is in place, the business plan is ... a lawyer steps into the room, clears her throat and asks ... not write that check, she says, until you learn more about ...
... - Are state government information technology consolidation projects ... Miszewski, the CIO for the State of Wisconsin, has ... are not unusual for large state projects. He has ... government CIOs, but are cost overruns, implementation delays, and ...
Cached Biology Technology:Why repealing the shareholder wage lien law makes sense 2Why repealing the shareholder wage lien law makes sense 3State IT failures are not inevitable 2State IT failures are not inevitable 3State IT failures are not inevitable 4State IT failures are not inevitable 5
(Date:11/15/2014)... -- While we may still be a few years away from ... to gain instant access to all that ailed his patients, ... tablets for monitoring and measuring our health are cropping up ... a tad Orwellian to some, but a new survey suggests ... opportunities into their healthcare regime. These are some ...
(Date:11/7/2014)... Calif. , Nov. 7, 2014  In conjunction with ... Police Departments, The Community Foundation of the Verdugos ... DNA JUSTICE PROJECT," a $250,000 initiative to keep ... initial phase. In its first six months of existence, the ... needed evidence support for local law enforcement. "Because ...
(Date:11/6/2014)... Baltimore, MD, November 6, 2014 - Insilico Medicine, ... in aging and age related diseases announced a ... medicine of cancer, Champions Oncology, Inc (OTC: CSBR). ... genomics for personalized medicine, but Champions Oncology,s TumorGraft ... can validate the chemotherapy regimen experimentally generating vast ...
Breaking Biology News(10 mins):Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... Dec. 6, 2010 Parascript, LLC, the image ... that its Signature Xpert was awarded best ... International Conference on Frontiers in Handwriting Recognition (ICFHR2010) ... 2010. Parascript was among seven participants representing a ...
... The season in which babies are born can have ... clocks function. That is the conclusion of a new ... Nature Neuroscience . The experiment provides the first ... and was conducted by Professor of Biological Sciences Douglas ...
... multiple sclerosis could be reversed by activating stem cells that ... has shown. Researchers from the Universities of Cambridge and ... known as myelin sheaths that protect nerve fibres ... showed how this mechanism can be exploited to make the ...
Cached Biology News:Parascript SignatureXpert Wins Forensic Signature Verification Competition 2Babies' biological clocks dramatically affected by birth light cycle 2Babies' biological clocks dramatically affected by birth light cycle 3Babies' biological clocks dramatically affected by birth light cycle 4Babies' biological clocks dramatically affected by birth light cycle 5Study reveals new possibility of reversing damage caused by MS 2
Assay Diluent Trial Pack, 4 x 100 mL...
... ZMD.474. Immunogen: Synthetic peptide derived ... mouse junctophilin-3. Specificity: Specific for ... protein. Reactivity: Mouse (positive controls: ... and heart tissues). Applications: Western ...
Rabbit anti-Junctophilin-4 (C-term)...
SpectroQuest single beam 4nm UV/Vis spectrophotometer; stand-alone unit; large angled LCD screen; large sample compartment...
Biology Products: